SARENSIS 28 0.035 MG — DIN 02411474
ETHINYL ESTRADIOL : 0.035 MG NORGESTIMATE : 0.250 MG · PATRIOT A DIVISION OF JANSSEN INC · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED PRE MARKET
What is SARENSIS 28?
SARENSIS 28 0.035 MG contains ETHINYL ESTRADIOL : 0.035 MG NORGESTIMATE : 0.250 MG. It is listed in the Health Canada Drug Product Database under DIN 02411474, held by PATRIOT A DIVISION OF JANSSEN INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled pre market, status dated 03-Aug-2017. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
Is there a generic Norgestimate And Estrogen in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
3 holders have a Canadian DIN containing Norgestimate And Estrogen, across 6 DINs, of which 0 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| JANSSEN INC | 2 | 0 | CYCLEN TABLETS (21 DAY), CYCLEN TABLETS (28 DAY) | No marketed DIN |
| NOVOPHARM LIMITED | 2 | 0 | PREVIFEM (21DAY), PREVIFEM (28DAY) | No marketed DIN |
| PATRIOT A DIVISION OF JANSSEN INC | 2 | 0 | SARENSIS 21, SARENSIS 28 | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 0.035 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Norgestimate And Estrogen |
|---|---|
| ATC code | G03AA11 |
| AHFS class | 68:12.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02411474 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2411474 |
| Brand name | SARENSIS 28 |
| Generic / active ingredient | ETHINYL ESTRADIOL : 0.035 MG NORGESTIMATE : 0.250 MG |
| Market authorization holder | PATRIOT A DIVISION OF JANSSEN INC |
| Health Canada schedule | Prescription |
| ATC code | G03AA11 |
| ATC anatomical main group | G — Genito-urinary system and sex hormones |
| ATC therapeutic subgroup | G03AA |
| Current status | CANCELLED PRE MARKET |
| Status date | 03-Aug-2017 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 6 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CYCLEN TABLETS (21 DAY) | 0.035 MG | TABLET | JANSSEN INC | CANCELLED POST MARKET | 01968440 |
| CYCLEN TABLETS (28 DAY) | 0.25 MG | TABLET | JANSSEN INC | CANCELLED POST MARKET | 01992872 |
| PREVIFEM (21DAY) | 0.035 MG | TABLET | NOVOPHARM LIMITED | CANCELLED PRE MARKET | 02320061 |
| PREVIFEM (28DAY) | 0.25 MG | TABLET | NOVOPHARM LIMITED | CANCELLED PRE MARKET | 02320088 |
| SARENSIS 21 | 0.250 MG | TABLET | PATRIOT A DIVISION OF JANSSEN INC | CANCELLED PRE MARKET | 02411466 |
2 · Same class — other molecules in ATC G03AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Levonorgestrel And Estrogen | ALESSE 21 · ALESSE 28 · ALYSENA 21 · ALYSENA 28 · +22 more | 26 | 18 | Yes |
| Drospirenone And Estrogen | DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS · DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS 21 · DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS 28 · DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS USP · +16 more | 20 | 10 | Yes |
| Desogestrel And Estrogen | APRI 21 · APRI 28 · FREYA 21 · FREYA 28 · +12 more | 16 | 10 | Yes |
| Norethisterone And Estrogen | BREVICON 0.5/35 21 TAB · BREVICON 0.5/35 28 TAB · BREVICON 0.5/35 TABLETS (21-DAY PACK) · BREVICON 0.5/35 TABLETS (28-DAY PACK) · +19 more | 25 | 6 | Yes |
| Norelgestromin And Estrogen | EVRA · EVRA -(6/0.75) | 2 | 1 | Yes |
| Drospirenone And Estetrol | NEXTSTELLIS | 1 | 1 | Yes |
| Norgestimate And Estrogen | CYCLEN TABLETS (21 DAY) · CYCLEN TABLETS (28 DAY) · PREVIFEM (21DAY) · PREVIFEM (28DAY) · +2 more | 6 | 0 | Not in Canada |
| Norgestrel And Estrogen | LO-FEMENAL 21 TABLETS · OVRAL 21 · OVRAL 21 TAB · OVRAL 28 TABLETS · +1 more | 5 | 0 | Not in Canada |
| Etynodiol And Estrogen | DEMULEN 30 (21 DAY PACK) · DEMULEN 30 (28 DAY PACK) · DEMULEN 50 (21 DAY PACK) · DEMULEN 50 (28 DAY PACK) | 4 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC G03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| G03AB | Desogestrel And Estrogen · Dienogest And Estrogen · Levonorgestrel And Estrogen · Norethisterone And Estrogen · Norgestimate And Estrogen · +2 more | 40 | 14 |
| G03AC | Drospirenone · Etonogestrel · Levonorgestrel · Medroxyprogesterone · Norethisterone · +1 more | 13 | 6 |
| G03AD | Levonorgestrel · Ulipristal | 14 | 5 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.